International Journal of Drug Delivery Technology
Volume 14, Issue 3

Design and Optimization of Solid Lipid Nanoparticles for Enhanced Therapeutic Activity of Linagliptin

Swathi Yambadi*, Vasudha Bakshi

School of Pharmacy, Anurag University, Venkatapur, Ghatkesar, Medchal-Malkajgiri, Hyderabad, Telangana, India. 

Received: 15th March, 2024; Revised: 23rd May, 2024; Accepted: 13th August, 2024; Available Online: 25th September, 2024 

ABSTRACT

To augment oral bioavailability, linagliptin (LGP) loaded solid lipid nanoparticles (SLNs) have been formed using the solvent evaporation technique of emulsification. Utilizing the Box Behken design (BBD), examining the relation between independent and dependent variables was possible. Particle size (PS), entrapment efficiency (EE), and in-vitro drug release (DR) studies were considered response factors, whereas the various concentrations of lipid carrier, surfactant, and co-surfactant were considered process variables for optimization. The design expert program was used to obtain the optimized batch. At 24 hours, it was discovered that the optimized batch expected responses for PS, %EE, and %DR were 105.83 nm, 81.19, and 96.69%, respectively. The observed PS, %EE, and %DR responses of the optimized batch at 24 hours were determined to be 101.36 nm, 80.56, and 96.31%, respectively. There is no interaction seen in the basic physical mixing of drug and polymer, according to the FTIR spectra of pure drugs, polymers, and drug and polymer mixtures. The optimized formulation’s average size was found to be 138 nm by the particle size analysis. Similarly, a value of 0.255 was found by the polydispersity index (PDI). This suggests that the SLN in the formulation has a homogeneous size dispersion. With a zeta value of -32.8 mV, stability is indicated. Linagliptin was effectively developed as a drug with a 24-hour sustained release. Wistar rats were used in the in-vivo evaluation of linagliptin SLN formulations. The drug bioavailability increased five times (a highly significant fivefold increase) in LGP-loaded SLNs (AUC0-t ≈ 134.5 μg*h/mL) compared to raw LGP (AUC0-t = 27.23 μg*h/mL).

Keywords: Linagliptin, Solid lipid nanoparticles, Box Behken design, Optimization. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.59

How to cite this article: Yambadi S, Bakshi V. Design and Optimization of Solid Lipid Nanoparticles for Enhanced Therapeutic Activity of Linagliptin. International Journal of Drug Delivery Technology. 2024;14(3):1668-1675.

REFERENCES

  1. Mishra V, Bansal KK, Verma A, Yadav N, Thakur S, Sudhakar K, Rosenholm Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems. Pharmaceutics. 2018;10(4):191. doi: 10.3390/pharmaceutics10040191. Available from: doi: 10.3390/ pharmaceutics10040191.
  2. Smith T, Affram K, Nottingham EL, Han B, Amissah F, Krishnan S, Trevino J, Agyare E. Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer. Sci. Rep. 2020;12(1):16989. doi: 10.1038/s41598-020-73218-6.
  3. Talarico L, Consumi M, Leone G, Tamasi G, Magnani Solid lipid nanoparticles produced via a coacervation method as promising carriers for controlled release of Quercetin. Molecules. 2021;26(9):2694. doi: 10.3390/molecules26092694.
  4. Tan CP, Schwarz K. Development and characterization of solid lipid nanoparticles (SLNs) made of cocoa butter: A factorial design study. J. Food Eng. 2018;231:30–41. doi: 10.1016/j. 2018.03.006.
  5. He J, Huang S, Sun X, Han L, Chang C, Zhang W, ZhongCarvacrol Loaded Solid Lipid Nanoparticles of Propylene Glycol Monopalmitate and Glyceryl Monostearate: Preparation, Characterization, and Synergistic Antimicrobial Activity. Nanomaterials. 2019;9(8):1162. doi: 10.3390/nano9081162.
  6. Ban C, Jo M, Park YH, Kim JH, Han JY, Lee KW, Kweon DH, Choi YJ. Enhancing the oral bioavailability of curcumin using solid lipid nanoparticles. Food Chem. 2020;302:125328. doi: 1016/j.foodchem.2019.125328.
  7. Borges A, De Freitas V, Mateus N, Fernandes I, Oliveira Solid lipid nanoparticles as carriers of natural phenolic compounds. Antioxidants. 2020;9(10):998. doi: 10.3390/antiox9100998.
  8. Singh H, Singh M, Singh N, Jain H, Goel H, Chawla Unraveling the Therapeutic Prospects of Solid Lipid Nanoparticles for the Treatment of Parasitic Diseases. International Journal of Drug Delivery Technology. 2024;14(1):447-462. Available from: doi: 10.25258/ijddt.14.1.64.
  9. Taghi HS, Abdulelah FM, Al-Karagully HJ. Solid Lipid Nanoparticle; A Potential Lipid-Based Drug Delivery International Journal of Drug Delivery Technology. 2021;11(2):582-586. Available from: doi: 10.25258/ijddt.11.2.61.
  10. Kumar R, Singh A, Garg N. Acoustic cavitation assisted hot melt mixing technique for solid lipid nanoparticles formulation, characterization, and controlled delivery of poorly water soluble J. Drug Deliv. Sci. Technol. 2019;54:101277. doi: 10.1016/j. jddst.2019.101277.
  11. Hassett KJ, Benenato KE, Jacquinet E, Lee A, Woods A,Yuzhakov O, Himansu S, Deterling J, Geilich BM, KetovaOptimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol. Ther. Nucleic Acids. 2019;15:1–11. doi: 10.1016/j.omtn.2019.01.013.
  12. Souto EB, Baldim I, Oliveira WP, Rao R, Yadav N, Gama FM, Mahant S. SLN, and NLC for topical, dermal, and transdermal drug Expert Opin. Drug Deliv. 2020;17(3):357–377. doi: 10.1080/17425247.2020.1727883.
  13. Singh C, Yashwant, Gupta AK, Garg Formulation Development and Evaluation of Divalproex Sodium Extended-release Tablets. International Journal of Drug Delivery Technology. 2022;12(4):1769-1773.DOI: 10.25258/ijddt.12.4.46
  14. Sgorla D, Lechanteur A, Almeida A, Sousa F, Melo E, Bunhak É, Mainardes R, Khalil, N, Cavalcanti O, Sarmento Development and characterization of lipid-polymeric nanoparticles for oral insulin delivery. Expert Opin. Drug Deliv. 2018;15:213–222. doi: 10.1080/17425247.2018.1420050.
  15. Dudhipala N, Janga KY, Gorre Comparative study of nisoldipine- loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: Preparation, characterization, permeation, and pharmacokinetic evaluation. Artif. Cells Nanomed. Biotechnol. 2018;46(sup2):616-625. doi: 10.1080/21691401.2018.1465068.
  16. Magalhães J, Chaves LL, Vieira AC, Santos SG, Pinheiro M, ReisOptimization of rifapentine-loaded lipid nanoparticles using a quality-by-design strategy. Pharmaceutics. 2020;12(1):75. doi: 10.3390/pharmaceutics12010075.